BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.9 USD | +3.18% |
|
+7.47% | -19.27% |
| 05:33pm | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
| Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
Financials (USD)
| Sales 2024 * | 9.52B | Sales 2025 * | 9.53B | Capitalization | 29.48B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.86B | Net income 2025 * | 2.21B | EV / Sales 2024 * | 3.45 x |
| Net Debt 2024 * | 3.38B | Net Debt 2025 * | 349M | EV / Sales 2025 * | 3.13 x |
| P/E ratio 2024 * |
15.5
x | P/E ratio 2025 * |
13.4
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
More news
| 1 day | +2.78% | ||
| 1 week | +6.72% | ||
| Current month | -3.79% | ||
| 1 month | -2.16% | ||
| 3 months | -15.26% | ||
| 6 months | -13.95% | ||
| Current year | -19.83% |
1 week
192.75
207.62
1 month
189.44217.57
Current year
189.44268.30
1 year
189.44319.76
3 years
187.16468.55
5 years
187.16468.55
10 years
187.16480.18
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 22-11-13 | |
| Director of Finance/CFO | 60 | 20-08-14 | |
Nicole Murphy
COO | Chief Operating Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 09-12-31 |
William Hawkins
BRD | Director/Board Member | 70 | 19-06-18 |
Caroline Dorsa
CHM | Chairman | 64 | 10-01-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 1 M€ | 0.00% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - | |
| 2.39% | 14,021 M€ | +4.45% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 208.9 | +3.18% | 1 893 844 |
| 24-04-25 | 202.5 | +0.23% | 1,590,300 |
| 24-04-24 | 202 | +4.56% | 3,265,676 |
| 24-04-23 | 193.2 | -0.48% | 1,461,694 |
| 24-04-22 | 194.1 | -0.14% | 1,119,536 |
Delayed Quote Nasdaq, April 26, 2024 at 11:51 am EDT
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
202.5
USD
Average target price
286.5
USD
Spread / Average Target
+41.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.83% | 29.48B | |
| -4.66% | 87.53B | |
| +2.63% | 40.42B | |
| +57.86% | 25.43B | |
| -17.78% | 11.49B | |
| -44.02% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B | |
| +2.19% | 7.67B |
- Stock Market
- Equities
- BIIB Stock
